Assessments of bone morphogenetic proteins 2 and 7 in treating nonunion

doi:10.3969/j.issn.2095-4344.2687

Abstract

Abstract:

BACKGROUND: Autologous bone transplantation combined with strong fixation is considered as the gold standard for the treatment of nonunion. At present, there are many cases in which bone nonunion is treated with bone morphogenetic proteins 2 and 7.

OBJECTIVE: To describe the osteogenic pathway of bone morphogenetic proteins at the gene level,

summarize the clinical cases of nonunion treated with bone morphogenetic protein, and compare the therapeutic effects of bone morphogenetic proteins 2 and 7 on nonunion, followed by evaluation and analysis.

METHODS: The first author used a computer to search the full-text database of Chinese journals, WanFang database and PubMed database. The key words were “BMP, nonunion, pathway, external fixator, ORIF, bone graft, infected nonunion, bone defect, osteoblast, osteoporosis " and 59 articles were finally included in the result analysis.

RESULTS AND CONCLUSION: Literature review indicates that the gene-level pathway of bone morphogenetic protein can provide therapeutic ideas in clinical practice. In the treatment of bone nonunion, bone morphogenetic proteins 2 and 7 are effective, but there are yet no specifications and standards for the use of bone morphogenetic proteins, such as usage amount and indications. From the overall treatment effect and the treatment effect on infected bone nonunion, we compare the use of bone morphogenetic proteins 2 and 7. The effect of bone morphogenetic protein 2 is better than that of bone morphogenetic protein 7, especially in the treatment of infected nonunion.

Key words: bone morphogenetic protein, nonunion, signaling pathway, bone morphogenetic protein 2, bone morphogenetic protein 7, bone graft, infected nonunion, bone defect, osteoblasts, osteogenic differentiation

CLC Number:

Cong Kai, Li Shanlong, Wang Fei, Cheng Hui, Li Baitong, Shang Jian.

Assessments of bone morphogenetic proteins 2 and 7 in treating nonunion [J]. Chinese Journal of Tissue Engineering Research, 2020, 24(26): 4243-4250.

Figures/Tables 2

References

[1] URIST MR. Bone: formation by autoinduction. Science. 1965;150 (3698):893-899.

[2] URIST MR, STRATES BS. The classic: bone morphogenetic protein. Clin Orthop Relat Res. 2009;467(12):3051-3062.

[3] MURRAY SS, BROCHMANN MURRAY EJ, WANG JC, et al. The history and histology of bone morphogenetic protein. Histol Histopathol. 2016;31(7):721-732.

[4] WANG M, LI J, YE Y, et al. SHED-derived conditioned exosomes enhance the osteogenic differentiation of PDLSCs via Wnt and BMP signaling in vitro. Differentiation. 2019;111:1-11.

[5] LOOZEN LD, VANDERSTEEN, A, KRAGTEN, AH, et al. Bone formation by heterodimers through non-viral gene delivery of BMP-2/6 and BMP-2/7. Eur Cell Mater. 2018;35:195-208.

[6] KAITO T, MORIMOTO T, MORI Y, et al. BMP-2/7 heterodimer strongly induces bone regeneration in the absence of increased soft tissue inflammation. Spine J. 2018;18(1):139-146.

[7] NEUGEBAUER JM, KWON S, KIM HS, et al. The prodomain of BMP4 is necessary and sufficient to generate stable BMP4/7 heterodimers with enhanced bioactivity in vivo. Proc Natl Acad Sci U S A. 2015;112(18):E2307-E2316.

[8] KATAGIRI T, WATABE T. Bone morphogenetic proteins. Cold Spring Harb Perspect Biol. 2016,8(6):a021899.

[9] ZHANG YE. Non-smad signaling pathways of the TGF-β family. Cold Spring Harb Perspect Biol. 2017;9(2):a022129.

[10] BAO LR, ZHAO WQ, LIN T, et al. miRNA profile of the human dental pulp cells during odontoblast differentiation induced by BMP-2. Shanghai Kou Qiang Yi Xue. 2017;26(5):476-483.

[11] KIM BG, LEE JH, AHN JM, et al. 'Two-stage double-technique hybrid (TSDTH)' identification strategy for the analysis of BMP2-induced transdifferentiation of premyoblast C2C12 cells to osteoblast. J Proteome Res. 2009;8(10):4441-4454 .

[12] HASSEL S, SCHMITT S, HARTUNG A, et al. Initiation of Smad-dependent and Smad-independent signaling via distinct BMP-receptor complexes. J Bone Joint Surg Am. 2003;85-A Suppl 3:44-51.

[13] NOHE A, HASSEL S, EHRLICH M, et al. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem. 2002;277(7):5330-5338.

[14] GUZMAN A, ZELMAN-FEMIAK M, BOERGERMANN JH, et al. SMAD versus non-SMAD signaling is determined by lateral mobility of bone morphogenetic protein (BMP) receptors. J Biol Chem. 2012;287(47):39492-39504.

[15] CHEN B, LI B, QI YJ, et al. Enhancement of tendon-to-bone healing after anterior cruciate ligament reconstruction using bone marrow-derived mesenchymal stem cells genetically modified with bFGF/BMP2. Sci Rep. 2016;6:25940.

[16] HE J, HAN X, WANG S, et al. Cell sheets of co-cultured BMP-2-modified bone marrow stromal cells and endothelial progenitor cells accelerate bone regeneration in vitro. Exp Ther Med. 2019;18(5):3333-3340.

[17] ROY S, ZHUANG Y, Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells. Front Med. 2018,12(4): 374-386.

[18] LOCKLIN RM, RIGGS BL, HICOK KC, et al.Assessment of gene regulation by bone morphogenetic protein 2 in human marrow stromal cells using gene array technology. J Bone Miner Res. 2001,16(12):2192-204.

[19] HAYASHI Y, HSIAO EC, SAMI S, et al. BMP-SMAD-ID promotes reprogramming to pluripotency by inhibiting p16/INK4A-dependent senescence. Proc Natl Acad Sci USA. 2016;113(46):13057-13062 .

[20] JIA Y, WANG, Z, ZANG, A, et al. Tetramethylpyrazine inhibits tumor growth of lung cancer through disrupting angiogenesis via BMP/Smad/Id-1 signaling. Int J Oncol. 2016;48(5):2079-2086.

[21] SHIN M, OHTE S, FUKUDA T, et al. Identification of a novel bone morphogenetic protein (BMP)-inducible transcript, BMP-inducible transcript-1, by utilizing the conserved BMP-responsive elements in the Id genes. J Bone Miner Metab. 2013;31(1):34-43.

[22] LEE KM, PARK KH, HWANG JS, et al. Inhibition of STAT5A promotes osteogenesis by DLX5 regulation. Cell Death Dis. 2018; 9(11):1136.

[23] CAO Y, LV Q, LV C. MicroRNA-153 suppresses the osteogenic differentiation of human mesenchymal stem cells by targeting bone morphogenetic protein receptor type II. Int J Mol Med. 2015; 36(3):760-766.

[24] MIYAUCHI Y, MIYAMOTO T. Suppressive effects for osteoclastogenesis regulated by RANKL signal. Clin Calcium. 2011;21(8):1141-1147.

[25] ZHANG J, ZHANG W, DAI J, et al. Overexpression of Dlx2 enhances osteogenic differentiation of BMSCs and MC3T3-E1 cells via direct upregulation of Osteocalcin and Alp. Int J Oral Sci. 2019;11(2):12.

[26] LUTTRELL LM, DAR MS, GESTY-PALMER D, et al. Transcriptomic characterization of signaling pathways associated with osteoblastic differentiation of MC-3T3E1 cells. PLoS One. 2019;14(1):e0204197 .

[27] VANYAI HK, GARNHAM A, MAY RE, et al. MOZ directs the distal-less homeobox gene expression program during craniofacial development. Development. 2019 doi: 10.1242/dev.175042.

[28] SUN S, YU M, FAN Z, et al. DLX3 regulates osteogenic differentiation of bone marrow mesenchymal stem cells via Wnt/β-catenin pathway mediated histone methylation of DKK4. Biochem Biophys Res Commun. 2019;516(1):171-176.

[29] LI Y FAN L, HU J, et al. MiR-26a Rescues bone regeneration deficiency of mesenchymal stem cells derived from osteoporotic mice. Mol Ther. 2015;23(8):1349-1357.

[30] SINGH M, DEL CARPIO-CANO FE, MONROY MA, et al. Homeodomain transcription factors regulate BMP-2-induced osteoactivin transcription in osteoblasts. J Cell Physiol. 2012; 227(1):390-399.

[31] YANG L, GE D, CAO X, et al. MiR-214 Attenuates osteogenic differentiation of mesenchymal stem cells via targeting FGFR1. Cell Physiol Biochem. 2016;38(2):809-820.

[32] DENG Y, WU S, ZHOU H, et al. Effects of a miR-31, Runx2, and Satb2 regulatory loop on the osteogenic differentiation of bone mesenchymal stem cells. Stem Cells Dev. 2013;22(16): 2278-2286.

[33] HUANG J, MENG Y, LIU Y, et al. MicroRNA-320a regulates the osteogenic differentiation of human bone marrow-derived mesenchymal stem cells by targeting HOXA10. Cell Physiol Biochem. 2016;38(1):40-48.

[34] HALCSIK E, FORNI MF, FUJITA A, et al. New insights in osteogenic differentiation revealed by mass spectrometric assessment of phosphorylated substrates in murine skin mesenchymal cells. BMC Cell Biol. 2013;14:47.

[35] JUN JH, YOON WJ, SEO SB, et al. BMP2-activated Erk/MAP kinase stabilizes Runx2 by increasing p300 levels and histone acetyltransferase activity. J Biol Chem. 2010;285(47): 36410-36419.

[36] KOSEKI T, GAO Y, OKAHASHI N, et al. Role of TGF-beta family in osteoclastogenesis induced by RANKL. Cell Signal. 2002;14(1): 31-36.

[37] BARCAK EA, BEEBE MJ, Bone morphogenetic protein: is there still a role in orthopedic trauma in 2017? Orthop Clin North Am. 2017;48(3):301-309.

[38] CATERINI R, POTENZA V, IPPOLITO E, et al. Treatment of recalcitrant atrophic non-union of the humeral shaft with BMP-7, autologous bone graft and hydroxyapatite pellets. Injury. 2016;47 Suppl 4:S71-S77.

[39] SINGH R, BLEIBLEH S, KANAKARIS NK, et al. Upper limb non-unions treated with BMP-7: efficacy and clinical results. Injury. 2016;47 Suppl 6:S33-S39.

[40] OLLIVIER M, GAY AM, CERLIER A, et al. Can we achieve bone healing using the diamond concept without bone grafting for recalcitrant tibial nonunions? Injury. 2015;46(7):1383-1388.

[41] MURENA L, CANTON G, VULCANO E, et al. Treatment of humeral shaft aseptic nonunions in elderly patients with opposite structural allograft, BMP-7, and mesenchymal stem cells. Orthopedics. 2014;37(2):e201-e206.

[42] LOWERY JW, ROSEN V. Bone morphogenetic protein-based therapeutic approaches. Cold Spring Harb Perspect Biol. 2018. doi: 10.1101/cshperspect.a022327.

[43] BISHOP, JA, PALANCA, AA, BELLINO, MJ, et al. Assessment of compromised fracture healing. J Am Acad Orthop Surg. 2012; 20(5):273-282.

[44] HAK, DJ, Editorial on "Epidemiology of fracture nonunion in 18 human bones". Ann Transl Med. 2017;5(Suppl 1):S19.

[45] NICODEMO A, CAPELLA M, DEREGIBUS M, et al. Nonunion of a sacral fracture refractory to bone grafting: internal fixation and osteogenic protein-1 (BMP-7) application. Musculoskelet Surg. 2011;95(2):157-161.

[46] HACKL S, HIERHOLZER C, FRIEDERICHS J, et al. Long-term outcome following additional rhBMP-7 application in revision surgery of aseptic humeral, femoral, and tibial shaft nonunion. BMC Musculoskelet Disord. 2017;18(1):342.

[47] CECCHI S, BENNET SJ, ARORA M, Bone morphogenetic protein-7: Review of signalling and efficacy in fracture healing. J Orthop Translat. 2016;4:28-34.

[48] MOGHADDAM-ALVANDI A, ZIMMERMANN G, BÜCHLER A, et al. Results of nonunion treatment with bone morphogenetic protein 7 (BMP-7). Unfallchirurg. 2012;115(6):518-526.

[49] TRESSLER MA, RICHARDS JE, SOFIANOS D, et al. Bone morphogenetic protein-2 compared to autologous iliac crest bone graft in the treatment of long bone nonunion. Orthopedics. 2011; 34(12):e877-e884.

[50] ABLOVE RH, ABRAMS SS. The use of BMP-2 and screw exchange in the treatment of scaphoid fracture non-union. Hand Surg. 2015;20(1):167-171.

[51] BRANNAN PS, GASTON RG, LOEFFLER BJ, et al. Complications with the use of BMP-2 in scaphoid nonunion surgery. J Hand Surg Am. 2016;41(5):602-608.

[52] CONWAY JD, SHABTAI L, BAUERNSCHUB A, et al. BMP-7 versus BMP-2 for the treatment of long bone nonunion. Orthopedics. 2014;37(12):e1049-e1057.

[53] HAUBRUCK P, TANNER MC, VLACHOPOULOS W, et al. Comparison of the clinical effectiveness of Bone Morphogenic Protein (BMP) -2 and -7 in the adjunct treatment of lower limb nonunions. Orthop Traumatol Surg Res. 2018;104(8):1241-1248.

[54] HISSNAUER TN, STIEL N, BABIN K, et al. Bone morphogenetic protein-2 for the treatment of congenital pseudarthrosis of the tibia or persistent tibial nonunion in children and adolescents: a retrospective study with a minimum 2-year follow-up. J Mater Sci Mater Med. 2017;28(4):60.

[55] PAPANNA MC, SALDANHA KA, KURIAN B, et al. The use of recombinant morphogenic protein-2(rhBMP-2) in children undergoing revision surgery for persistent non-union. Strategies Trauma Limb Reconstr. 2016;11(1):53-58.

[56] RICHARDS BS, OETGEN ME, JOHNSTON CE. The use of rhBMP-2 for the treatment of congenital pseudarthrosis of the tibia: a case series. J Bone Joint Surg Am. 2010;92(1):177-185.

[57] RITTING AW, WEBER EW, LEE MC. Exaggerated inflammatory response and bony resorption from BMP-2 use in a pediatric forearm nonunion. J Hand Surg Am. 2012;37(2):316-321.

[58] GIANNOUDIS PV, KANAKARIS NK, DIMITRIOU R, et al. The synergistic effect of autograft and BMP-7 in the treatment of atrophic nonunions. Clin Orthop Relat Res. 2009;467(12): 3239-3248.

[59]AGRAWAL V, SINHA M, A review on carrier systems for bone morphogenetic protein-2. J Biomed Mater Res B Appl Biomater. 2017;105(4):904-925.